Idioma:

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

Adorini, Luciano ; Pruzanski, Mark ; Shapiro, David

Drug discovery today, 2012-09, Vol.17 (17-18), p.988-997 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Autor: Adorini, Luciano ; Pruzanski, Mark ; Shapiro, David
Assuntos: Animals ; Biological and medical sciences ; Chenodeoxycholic Acid - analogs & derivatives ; Chenodeoxycholic Acid - pharmacology ; Chenodeoxycholic Acid - therapeutic use ; Fatty Liver - drug therapy ; Fatty Liver - metabolism ; General pharmacology ; Humans ; Medical sciences ; Non-alcoholic Fatty Liver Disease ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Receptors, Cytoplasmic and Nuclear - agonists ; Receptors, Cytoplasmic and Nuclear - metabolism
É parte de: Drug discovery today, 2012-09, Vol.17 (17-18), p.988-997
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: ► FXR is the bile acid nuclear receptor regulating lipid and glucose metabolism, and inflammatory responses. ► FXR-mediated activities have promoted a new understanding of bile acids as hormones with potential for multiple therapeutic applications. ► OCA is a potent and selective clinical-stage FXR agonist. ► Preclinical and clinical data support further clinical testing of OCA in NAFLD/NASH patients. Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver condition evolving in a proportion of patients into nonalcoholic steatohepatitis (NASH), an aggressive form of NAFLD associated with increased cardiovascular mortality and significant risk of progressive liver disease, including fibrosis, cirrhosis and hepatocellular carcinoma. At present, no specific therapies for NASH exist. In this review, we examine the evidence supporting activation of the farnesoid X receptor (FXR), a nuclear hormone receptor regulated by bile acids (BAs), for the treatment of NASH. We also discuss the potential of the semi-synthetic BA derivative obeticholic acid (OCA), a first-in-class FXR agonist, as a safe and effective drug to address this significant unmet medical need.
Editor: Kidlington: Elsevier Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

Adorini, Luciano ; Pruzanski, Mark ; Shapiro, David

Kidlington: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.